Regenxbio (RGNX) EBITDA Margin (2014 - 2025)
Regenxbio (RGNX) recorded quarterly EBITDA Margin of 221.46% in Q4 2025, down 6.47% quarter-over-quarter from 207.99% in Q3 2025, and up 2057.0% on a YoY basis from 10.27% in Q4 2024.
Regenxbio (RGNX) EBITDA Margin (2014 - 2025) Analysis & Trends
Regenxbio's EBITDA Margin history runs 12 years deep, the most recent figure standing at 221.46% for Q4 2025.
- In Q4 2025, EBITDA Margin rose 2057.0% year-over-year to 221.46%; the TTM figure through Dec 2025 stood at 113.72% (up 15439.0% YoY), while the FY2025 annual figure was 113.72%, up 15439.0% from the prior year.
- EBITDA Margin was 221.46% for Q4 2025 at Regenxbio, down from 207.99% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 73.43% in Q4 2021 to a low of 397.71% in Q1 2024.
- Historically, EBITDA Margin has averaged 237.81% across 5 years, with a median of 240.69% in 2024.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin tumbled 25553 bps in 2022, then surged 40452 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 73.43% in 2021, then sank by 348 bps to 182.1% in 2022, then plunged by 48 bps to 269.68% in 2023, then gained by 10 bps to 242.03% in 2024, then rose by 9 bps to 221.46% in 2025.
- The last three EBITDA Margin figures came in at 221.46% (Q4 2025), 207.99% (Q3 2025), and 331.75% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Regenxbio | 315.11 Mn | 85.04 Mn | - | -221.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -221.46% |
| Sep 30, 2025 | -207.99% |
| Jun 30, 2025 | -331.75% |
| Mar 31, 2025 | 6.81% |
| Dec 31, 2024 | -242.03% |
| Sep 30, 2024 | -239.34% |
| Jun 30, 2024 | -233.35% |
| Mar 31, 2024 | -397.71% |
| Dec 31, 2023 | -269.68% |
| Sep 30, 2023 | -204.69% |
| Jun 30, 2023 | -353.09% |
| Mar 31, 2023 | -328.65% |
| Dec 31, 2022 | -182.10% |
| Sep 30, 2022 | -297.89% |
| Jun 30, 2022 | -217.44% |
| Mar 31, 2022 | -387.54% |
| Dec 31, 2021 | 73.43% |
| Sep 30, 2021 | -189.89% |
| Jun 30, 2021 | -261.07% |
| Mar 31, 2021 | -270.85% |